Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCK | P08631 | 5/20 | 0.70 |
| ▸ | BTK | Q06187 | 3/20 | 0.70 |
| ▸ | LCK | P06239 | 14/20 | 0.69 |
| ▸ | ABL1 | P00519 | 6/20 | 0.61 |
| ▸ | SRC | P12931 | 5/20 | 0.61 |
| ▸ | EGFR | P00533 | 3/20 | 0.61 |
| ▸ | FYN | P06241 | 3/20 | 0.61 |
| ▸ | YES1 | P07947 | 3/20 | 0.61 |
| ▸ | LYN | P07948 | 3/20 | 0.61 |
| ▸ | KIT | P10721 | 3/20 | 0.61 |
| ▸ | BCR | P11274 | 3/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.61 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.61 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.61 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.61 |
| ▸ | CSF1R | P07333 | 2/20 | 0.61 |
| ▸ | RET | P07949 | 2/20 | 0.61 |
| ▸ | BRAF | P15056 | 2/20 | 0.61 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.61 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30712614 | 1.00 | HCK (0.70) | HCKBTKLCKABL1SRC | |
| SCHEMBL19205414 | 0.96 | HCK (0.66) | HCKBTKLCKABL1SRC | |
| SCHEMBL775273 | 0.90 | LCK (0.76) | HCKBTKLCKABL1SRC | |
| SCHEMBL19240700 | 0.89 | HCK (0.57) | HCKBTKLCKABL1SRC | |
| SCHEMBL18070206 | 0.85 | LCK (0.81) | HCKBTKLCKABL1SRC | |
| SCHEMBL774500 | 0.83 | LCK (0.91) | HCKBTKLCKABL1SRC | |
| SCHEMBL19205385 | 0.83 | HCK (1.00) | HCKBTKLCKABL1SRC | |
| SCHEMBL19205383 | 0.83 | HCK (1.00) | HCKBTKLCKABL1SRC | |
| SCHEMBL773654 | 0.82 | LCK (0.91) | HCKBTKLCKABL1SRC | |
| SCHEMBL13982226 | 0.82 | LCK (0.77) | HCKBTKLCKABL1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3715346-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2024-01-03 | — | — | EP | disclosed |
| US-10844077-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-10844077-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| EP-3715346-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | Dana-Farber Cancer Institute (US) | 2020-09-30 | — | — | EP | disclosed |
| US-20200165267-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-20200165267-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| EP-3209648-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2020-03-11 | — | — | EP | disclosed |
| US-10464949-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10464949-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190119301-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190119301-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10112957-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-3209648-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | Dana-Farber Cancer Institute, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165267-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, MCL1 | HCK 6/4885BTK 1/4885LCK 11/4885 |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, BCL9 | HCK 4/4885BTK 1/4885LCK 11/4885 |
| US-20190119301-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, BCL9 | HCK 4/4885BTK 1/4885LCK 11/4885 |
| US-10844077-B2 | Thiazolyl-containing compounds for treating proliferative diseases | BTK, BCL9L, MCL1 | HCK 6/4885BTK 1/4885LCK 11/4885 |
| US-10464949-B2 | Thiazolyl-containing compounds for treating proliferative diseases | BTK, BCL9L, BCL9 | HCK 4/4885BTK 1/4885LCK 11/4885 |
| US-10112957-B2 | Thiazolyl-containing compounds for treating proliferative diseases | BTK, BCL9L, BCL9 | HCK 4/4885BTK 1/4885LCK 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.